bupivacaine, and neurotoxic reactions after the use of lignocaine for intravenous regional analgesia. Symptoms have ranged from headache and dizziness to loss of consciousness and convulsions.2 4 Reports of adverse reactions after intravenous regional analgesia with bupivacaine are few and the symptoms minimal.' Ware reported mild transient drowsiness after release of the cuff in only one patient out of a total of 2500 using 1-5 mg/kg of 0 2%, bupivacaine for intravenous regional analgesia.2
The low incidence of adverse effects is thought to be due to the high protein-binding property of bupivacaine. Normally over 90% is bound to plasma proteins and consequently very little "free" drug is available for systemic action. Measurements of peak plasma concentrations after intravenous regional analgesia with bupivacaine also confirm a wide safety margin. Peak concentrations occur at about three minutes after deflation of the cuff (840 ng/ml). That is about half the accepted minimum toxic concentration for this drug (1600 ng/ml). Eleven patients were in group 1, 20 in group 2, seven in group 3, and none in group 4. Linoleic acid, expressed as percentage of total triglyceride fatty acids, was 25-6±7-4%, 21-3±8-20%b, and 14-7+6%,' for groups 1, 2, and 3 respectively, agreeing with the dietitian's grading. Total cholesterol in all 39 patients fell from 6-2+1-5 mmol/l (242+59 mg/100 ml) before to 51+1-3 mmol/l (199+51 mg/100 ml) at the end of the dietary period (p <0 00002). Mean values of total cholesterol and triglycerides before and after diet and of cholesterol fractions after diet are shown in the table. Overall triglyceride concentrations were identical before and after the diet (2-5±1-0 mmol/l, 213+85 mg/100 ml) but concentrations were significantly lower after diet in group 1 than in group 3 (see table) . Mean body weights (measured after dialysis) were identical before and after the dietary period (59 kg). There were no significant changes in body weight in any of the dietary groups.
Comment
The diet was acceptable to most patients; those who complied best showed a reduction in total cholesterol and a more "favourable" ratio of high density lipoprotein cholesterol to low density lipoprotein cholesterol. Although there was no overall reduction in triglycerides, concentrations were lowest in those with the best dietary compliance and vice versa. Diet is an effective and acceptable treatment for dialysis hyperlipidaemia, but any long-term clinical benefit of lowering lipid concentrations in these patients remains unproved.
We thank Robin Carter and Richard Jelfs, who performed the laboratory assays; Joan Osmond for administrative help; and Alan Cahill for taking the blood samples. *p<0-02 compared with triglyceride concentrations after diet in "poor compliance" group.
Conversion: SI to traditional units-Cholesterol: 1 mmol/I 38 6 mg/100 ml. Triglycerides: 1 mmol/l 88-5 mg/100 ml.
